Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

[1]  H. Hurwitz,et al.  Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab , 2013, Cancer medicine.

[2]  F. Saad,et al.  Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Berchuck,et al.  A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer , 2012, Clinical Cancer Research.

[4]  C. Augustine,et al.  Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy. , 2012 .

[5]  E. Vokes,et al.  Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium , 2012, Investigational New Drugs.

[6]  K. Blackwell,et al.  Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing , 2011, Clinical Cancer Research.

[7]  W. Messersmith,et al.  Current status of SRC inhibitors in solid tumor malignancies. , 2011, The oncologist.

[8]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[9]  S. Lippman,et al.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Hudis,et al.  Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. , 2010 .

[11]  E. Kohn,et al.  Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors. , 2010 .

[12]  Eric B Haura,et al.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Gradishar,et al.  Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy Data from Phase 1 Study CA180-004. , 2009 .

[14]  G. Scagliotti,et al.  Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin , 2009, Molecular Cancer Therapeutics.

[15]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[16]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Ellis,et al.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. , 2009, Cancer research.

[18]  H. Döhner,et al.  Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells , 2009, British journal of haematology.

[19]  M. Guba,et al.  Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling , 2008, Oncogene.

[20]  J. Hainsworth,et al.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Kopetz,et al.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis , 2008, Cell and Tissue Research.

[23]  C. Dive,et al.  Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity , 2006, British Journal of Cancer.

[24]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[25]  Paul Workman,et al.  Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[26]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[27]  Peter F Thall,et al.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. , 2003, Gynecologic oncology.

[28]  Y. M. Lee,et al.  TNF-related Activation-induced Cytokine (TRANCE) Induces Angiogenesis through the Activation of Src and Phospholipase C (PLC) in Human Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[29]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[30]  L. Ellis,et al.  Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src * , 1998, The Journal of Biological Chemistry.

[31]  Hua Yu,et al.  Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential , 1997, Oncogene.

[32]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[33]  H. Kawakatsu,et al.  A New Monoclonal Antibody Which Selectively Recognizes the Active Form of Src Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[34]  S. Curley,et al.  Site-specific differences in pp60c-src activity in human colorectal metastases. , 1993, The Journal of surgical research.

[35]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[36]  J. Pipas,et al.  pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.

[37]  N. Rosen,et al.  Activation of pp60c-src protein kinase activity in human colon carcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.